flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
PHASE2CompletedINTERVENTIONAL
Timeline
Start Date
February 28, 1998
Study Completion Date
March 31, 2007
Conditions
Stage IV MelanomaStage IV Renal Cell CancerRecurrent Renal Cell CancerRecurrent Melanoma
Interventions
DRUG
flt3 ligand
DRUG
gp100 antigen
DRUG
MART-1 antigen
DRUG
Montanide ISA-51
DRUG
tyrosinase peptide
Trial Locations (1)
20892
Surgery Branch, Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00019396 - flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer | Biotech Hunter | Biotech Hunter